ENANTA PHARMACEUTICALS INC Quarterly Share-based Payment Arrangement, Expense in USD from Q4 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enanta Pharmaceuticals Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q4 2015 to Q2 2024.
  • Enanta Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $5.42M, a 22.6% decline year-over-year.
  • Enanta Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $25.8M, a 8.97% decline year-over-year.
  • Enanta Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2023 was $28.2M, a 4.62% increase from 2022.
  • Enanta Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $27M, a 28.5% increase from 2021.
  • Enanta Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2021 was $21M, a 7.23% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $25.8M $5.42M -$1.58M -22.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $27.4M $5.56M -$1.8M -24.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $29.2M $8.1M +$960K +13.4% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-08
Q3 2023 $28.2M $6.72M -$117K -1.71% Jul 1, 2023 Sep 30, 2023 10-K 2023-11-22
Q2 2023 $28.3M $7M -$605K -7.96% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $28.9M $7.36M +$892K +13.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $28M $7.14M +$1.08M +17.8% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-08
Q3 2022 $27M $6.83M +$1.48M +27.6% Jul 1, 2022 Sep 30, 2022 10-K 2023-11-22
Q2 2022 $25.5M $7.6M +$2.13M +38.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $23.4M $6.47M +$1.19M +22.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $22.2M $6.06M +$1.18M +24.1% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-08
Q3 2021 $21M $5.35M +$608K +12.8% Jul 1, 2021 Sep 30, 2021 10-K 2023-11-22
Q2 2021 $20.4M $5.48M +$720K +15.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $19.7M $5.28M +$303K +6.09% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $19.4M $4.88M -$215K -4.22% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $19.6M $4.75M +$233K +5.16% Jul 1, 2020 Sep 30, 2020 10-K 2022-11-23
Q2 2020 $19.3M $4.76M +$591K +14.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $18.8M $4.98M +$270K +5.74% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $18.5M $5.1M -$745K -12.8% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 $19.2M $4.51M +$402K +9.78% Jul 1, 2019 Sep 30, 2019 10-K 2021-11-24
Q2 2019 $18.8M $4.16M +$139K +3.45% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $18.7M $4.71M +$1.12M +31.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $17.6M $5.84M +$1.72M +41.8% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 $15.8M $4.11M +$900K +28% Jul 1, 2018 Sep 30, 2018 10-K 2020-11-25
Q2 2018 $14.9M $4.03M +$923K +29.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $14M $3.59M +$98K +2.81% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $13.9M $4.12M +$853K +26.1% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-08
Q3 2017 $13.1M $3.21M +$700K +27.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-11-27
Q2 2017 $12.4M $3.1M +$632K +25.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $11.7M $3.49M +$1.11M +46.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $10.6M $3.27M +$1.28M +64% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-09
Q3 2016 $9.35M $2.51M Jul 1, 2016 Sep 30, 2016 10-K 2018-11-29
Q2 2016 $2.47M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $2.38M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $1.99M Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.